<div id="readability-page-1">Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market MINNEAPOLIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. ( PETV ) , in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced the launch of PetVivo.ai, a new artificial intelligence platform delivering a customer acquisition cost of $42.53—a 50–89% reduction compared to the $80–$400 typically spent by veterinary practices. The platform generates qualified leads for $3 per pet parent (versus $15–$45 through traditional digital advertising) and uses automated AI engagement to convert these leads into paying customers. This launch marks a major strategic move for PetVivo Holdings ( PETV ) as the company expands from traditional medical device sales—historically generating 30–40% margins—into a high-margin AI Software-as-a-Service (SaaS) model with 80–90% margins, recurring revenue, and significant scalability. The Problem Although the pet care industry now exceeds $150 billion annually, veterinary practices face a widening gap in how they reach today’s pet owners. Gen Z and Millennial pet parents account for 57% of all pet owners and expect modern digital experiences, yet many practices still depend on outdated marketing methods such as TV advertising and direct mail. &#34;Veterinary practices spend $80–$400 per new client depending on their marketing approach,&#34; said John Lai, Chief Executive Officer. &#34;Our AI generates qualified leads at just $3 each and converts them automatically. In our beta program, the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53—achieving 50–89% savings without the need for promotional discounting.&#34; The Solution PetVivo.ai solves this problem through a suite of nine specialized AI agents operating continuously: Client Discovery, Campaign Manager, Engagement, Analytics, Content Creation, Reputation, Compliance, ROI Optimization, and Practice Integration. Together, these agents connect practices with millions of engaged pet parents through a two-sided ecosystem. Industry-Leading Economics The platform’s economics were validated in a 50-practice beta program: <ul type="disc"><li>Lead Generation: $3 per qualified pet parent (vs. $15–$45 traditional)</li><li>Customer Acquisition Cost: $42.53 blended CAC (vs. $80–$400 typical)</li><li>Beta Results: 47 new clients median over 6 months (range: 12–124)</li><li>Pricing: $1,999/month for the Professional tier</li><li>LTV/CAC Ratio: 25:1 (best-in-class)</li><li>Payback Period: 1 month</li><li>Gross Margins: 80–90% </li></ul> Market Opportunity PetVivo.ai targets 30,000 U.S. veterinary practices and more than 100,000 globally. Even conservative adoption forecasts indicate strong scaling potential: <ul type="disc"><li>Year 1: 500 practices → $12M ARR</li><li>Year 3: 5,000 practices → $180M ARR</li><li>Year 5: 10,000 practices → $360M ARR </li></ul> The Catalyst The launch serves as a major catalyst for re-valuing the company as it transitions from traditional medical device revenue multiples (1–2x revenue) to AI SaaS multiples (15–30x revenue). Comparable companies such as Salesforce, HubSpot, Veeva Systems, and C3.ai trade at median multiples near 15x, suggesting potential 5–10x valuation upside as PetVivo.ai scales. &#34;We are currently valued as a medical device company while building an AI SaaS platform with far superior economics,&#34; added Mr. Lai. &#34;As revenue grows, we expect meaningful valuation re-rating.&#34; Competitive Advantages PetVivo.ai holds a first-mover advantage with no direct AI competitors, strong two-sided network effects, and existing relationships with 1,200 veterinary clinic distributors (with plans to target in excess of an additional 7,000). Deep integrations with practice management systems further accelerate adoption and reduce onboarding friction. Commercial Launch Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups at www.petvivo.ai, a 14-day free trial, three pricing tiers, and both direct-sales and self-service onboarding. About PetVivo Holdings, Inc. ( PETV ) PetVivo Holdings Inc. ( PETV ) , in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo ( PETV ) has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. Company Contact John Lai, CEO PetVivo Holdings, Inc. ( PETV ) Email Contact Tel (952) 405-6216 Forward-Looking commercial Statements The foregoing information regarding PetVivo Holdings, Inc. ( PETV ) (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Image: https://www.globenewswire.com/newsroom/ti?nf=OTU5MTkyMiM3MjkxNzc3IzUwMDA2ODIxMQ== Image: https://ml.globenewswire.com/media/NDliMzJkMDItNzdkNi00M2NkLTg2MGItMzQzZThiMjhjODg1LTUwMDA2ODIxMS0yMDI1LTExLTI1LWVu/tiny/PetVivo-Holdings-Inc-.png Image: Primary Logo Source: PetVivo Holdings, Inc. ( PETV )</div>

PETV

PetVivo Holdings, Inc.推出了 PetVivo.ai，这是一个人工智能平台，可以将兽医客户获取成本降低 50-89%，客户获取成本为 42.53 美元，而典型成本为 80-400 美元。该平台使用九个人工智能代理以每位宠物家长 3 美元的成本生成潜在客户，并将其转化为客户。这一战略举措使 PetVivo 从医疗设备销售转型为高利润的人工智能软件即服务（SaaS）模式，旨在实现显著的市场增长和估值重估

PetVivo 推出 AI 平台，将兽医客户获取成本降低 50% 至 89%